Logo image of QNRX

QUOIN PHARMACEUTICALS LT-ADR (QNRX) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:QNRX - US74907L4095 - ADR

9.97 USD
-0.48 (-4.59%)
Last: 1/21/2026, 8:00:01 PM
13.75 USD
+3.78 (+37.91%)
After Hours: 1/7/2026, 8:00:01 PM
Fundamental Rating

1

QNRX gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 525 industry peers in the Biotechnology industry. QNRX may be in some trouble as it scores bad on both profitability and health. QNRX does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

  • QNRX had negative earnings in the past year.
  • QNRX had a negative operating cash flow in the past year.
  • QNRX had negative earnings in each of the past 5 years.
  • In the past 5 years QNRX always reported negative operating cash flow.
QNRX Yearly Net Income VS EBIT VS OCF VS FCFQNRX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -5M -10M -15M -20M

1.2 Ratios

  • QNRX's Return On Assets of -214.33% is on the low side compared to the rest of the industry. QNRX is outperformed by 88.57% of its industry peers.
Industry RankSector Rank
ROA -214.33%
ROE N/A
ROIC N/A
ROA(3y)-64.59%
ROA(5y)-101.87%
ROE(3y)-126.09%
ROE(5y)-751.54%
ROIC(3y)N/A
ROIC(5y)N/A
QNRX Yearly ROA, ROE, ROICQNRX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 -1K -2K -3K

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for QNRX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
QNRX Yearly Profit, Operating, Gross MarginsQNRX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024

More info and screens

1

2. Health

2.1 Basic Checks

  • The number of shares outstanding for QNRX has been increased compared to 1 year ago.
  • The number of shares outstanding for QNRX has been increased compared to 5 years ago.
  • Compared to 1 year ago, QNRX has an improved debt to assets ratio.
QNRX Yearly Shares OutstandingQNRX Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
QNRX Yearly Total Debt VS Total AssetsQNRX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M

2.2 Solvency

  • QNRX has an Altman-Z score of -21.07. This is a bad value and indicates that QNRX is not financially healthy and even has some risk of bankruptcy.
  • The Altman-Z score of QNRX (-21.07) is worse than 82.86% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -21.07
ROIC/WACCN/A
WACCN/A
QNRX Yearly LT Debt VS Equity VS FCFQNRX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 5M -5M

2.3 Liquidity

  • A Current Ratio of 1.04 indicates that QNRX should not have too much problems paying its short term obligations.
  • Looking at the Current ratio, with a value of 1.04, QNRX is doing worse than 85.71% of the companies in the same industry.
  • A Quick Ratio of 1.04 indicates that QNRX should not have too much problems paying its short term obligations.
  • QNRX has a worse Quick ratio (1.04) than 84.76% of its industry peers.
Industry RankSector Rank
Current Ratio 1.04
Quick Ratio 1.04
QNRX Yearly Current Assets VS Current LiabilitesQNRX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 5M 10M

More info and screens

1

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 77.61% over the past year.
EPS 1Y (TTM)77.61%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%59.21%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • The Earnings Per Share is expected to grow by 20.76% on average over the next years. This is a very strong growth
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y78.26%
EPS Next 2Y38.63%
EPS Next 3Y25.85%
EPS Next 5Y20.76%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
QNRX Yearly Revenue VS EstimatesQNRX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2026 2027 2028 2029 2030 2031 50M 100M 150M
QNRX Yearly EPS VS EstimatesQNRX Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2021 2022 2023 2024 2025 2026 2027 2028 2029 0 -50K -100K -150K

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

  • QNRX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year QNRX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
QNRX Price Earnings VS Forward Price EarningsQNRX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
QNRX Per share dataQNRX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share -10 -20 -30

4.3 Compensation for Growth

  • A more expensive valuation may be justified as QNRX's earnings are expected to grow with 25.85% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y38.63%
EPS Next 3Y25.85%

More info and screens

0

5. Dividend

5.1 Amount

  • No dividends for QNRX!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

QUOIN PHARMACEUTICALS LT-ADR

NASDAQ:QNRX (1/21/2026, 8:00:01 PM)

After market: 13.75 +3.78 (+37.91%)

9.97

-0.48 (-4.59%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-06
Earnings (Next)03-11
Inst Owners38.35%
Inst Owner Change5151.31%
Ins Owners6.82%
Ins Owner Change1.03%
Market Cap8.36M
Revenue(TTM)N/A
Net Income(TTM)-13.77M
Analysts82.5
Price Target42.5 (326.28%)
Short Float %3.82%
Short Ratio0.07
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-7.64%
Min EPS beat(2)-32.19%
Max EPS beat(2)16.91%
EPS beat(4)2
Avg EPS beat(4)1.27%
Min EPS beat(4)-32.19%
Max EPS beat(4)25.4%
EPS beat(8)5
Avg EPS beat(8)2.22%
EPS beat(12)8
Avg EPS beat(12)7.54%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)51.52%
EPS NQ rev (1m)0%
EPS NQ rev (3m)34.32%
EPS NY rev (1m)0%
EPS NY rev (3m)18.2%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-31.74
EYN/A
EPS(NY)-6.35
Fwd EYN/A
FCF(TTM)-12.8
FCFYN/A
OCF(TTM)-12.8
OCFYN/A
SpS0
BVpS-1.45
TBVpS-1.93
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -214.33%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-64.59%
ROA(5y)-101.87%
ROE(3y)-126.09%
ROE(5y)-751.54%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.04
Quick Ratio 1.04
Altman-Z -21.07
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)77.61%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%59.21%
EPS Next Y78.26%
EPS Next 2Y38.63%
EPS Next 3Y25.85%
EPS Next 5Y20.76%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-51.75%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-63.18%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-63.18%
OCF growth 3YN/A
OCF growth 5YN/A

QUOIN PHARMACEUTICALS LT-ADR / QNRX FAQ

What is the ChartMill fundamental rating of QUOIN PHARMACEUTICALS LT-ADR (QNRX) stock?

ChartMill assigns a fundamental rating of 1 / 10 to QNRX.


Can you provide the valuation status for QUOIN PHARMACEUTICALS LT-ADR?

ChartMill assigns a valuation rating of 1 / 10 to QUOIN PHARMACEUTICALS LT-ADR (QNRX). This can be considered as Overvalued.


Can you provide the profitability details for QUOIN PHARMACEUTICALS LT-ADR?

QUOIN PHARMACEUTICALS LT-ADR (QNRX) has a profitability rating of 0 / 10.


Can you provide the financial health for QNRX stock?

The financial health rating of QUOIN PHARMACEUTICALS LT-ADR (QNRX) is 1 / 10.


Can you provide the expected EPS growth for QNRX stock?

The Earnings per Share (EPS) of QUOIN PHARMACEUTICALS LT-ADR (QNRX) is expected to grow by 78.26% in the next year.